+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation



Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation



Journal of Cardiology 68(6): 517-522



Triple antithrombotic therapy increases the risk of bleeding events in patients undergoing percutaneous coronary intervention (PCI) compared with dual anti-platelet therapy (DAPT). However, whether warfarin control is associated with reduced cardiovascular events and major bleeding events in patients undergoing PCI with triple antithrombotic therapy is uncertain. We investigated 1207 consecutive patients who underwent PCI between 2004 and 2011. Major bleeding complications and major adverse cardiac and cerebrovascular events (MACCE) defined as all-cause death, acute coronary syndrome, target vessel revascularization, and stroke were compared between groups of patients who received either triple antithrombotic therapy or DAPT. Triple antithrombotic therapy was administered to 95 (7.9%) patients. The mean international normalized ratio of prothrombin time (PT-INR) was 1.8. The target PT-INR level was set between 1.6 and 2.6 and the ratio (%) of time in the therapeutic range (TTR) was calculated. The median TTR was 78.4% (interquartile range, 67.4-87.6%). Kaplan-Meier survival curves showed that warfarin therapy was not associated with MACCE (p=0.89) and major bleeding (p=0.80). Multivariable Cox regression analysis revealed that triple antithrombotic therapy was not an independent predictor of MACCE and major bleeding. Triple antithrombotic therapy does not increase the occurrence of MACCE and major bleeding complications, if the warfarin dose is tightly controlled with a lower INR.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057139340

Download citation: RISBibTeXText

PMID: 27021470

DOI: 10.1016/j.jjcc.2015.10.019


Related references

A new scoring system (DAIGA) for predicting bleeding complications in atrial fibrillation patients after drug-eluting stent implantation with triple antithrombotic therapy. International Journal of Cardiology 223: 985-991, 2016

Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range. Circulation. Cardiovascular Interventions 6(4): 444-451, 2013

Short- and long-term efficacy and safety of triple vs. dual antithrombotic therapy in patients with drug-eluting stent implantation and an indication for oral anticoagulation: a meta-analysis. International Journal of Clinical Pharmacology and Therapeutics 54(12): 950-965, 2016

Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Catheterization and Cardiovascular Interventions 80(3): 395-405, 2012

Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding. Evidence-BasedMedicine20(3):99, 2015

Long-term dual antiplatelet treatment and bleeding complications in diabetic patients treated with drug eluting stent implantation. International Journal of Cardiology. Heart and Vasculature 5: 57-62, 2014

Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). American Heart Journal 160(3): E21; Author Reply E23, 2010

TCT-475 Triple Antithrombotic Therapy versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation undergoing Drug-eluting Stent Implantation. Journal of the American College of Cardiology 64(11): B139-B140, 2014

Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. Coronary Artery Disease 26(5): 372-380, 2015

Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. Journal of the American College of Cardiology 57(3): 280-289, 2011

Frequency and predictors of bleeding events after 2nd generation drug-eluting stent implantation differ depending on time after implantation. Journal of Cardiology 69(4): 632-639, 2017

Long-term (8 year) outcomes and predictors of major adverse cardiac events after full metal jacket drug-eluting stent implantation. Catheterization and Cardiovascular Interventions 84(3): 361-365, 2014

Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials 11: 87, 2010

Bleeding complications after implantation of active cardiovascular implantable devices in an era of triple therapy and novel antithrombotic drugs. European Heart Journal 34(Suppl 1): P3653-P3653, 2013

AS-163: Long-Term Major Cardiac Events and Hospitalization-Free Survival After Drug-Eluting Stent Implantation in Patients with Diabetes Mellitus: 5-Year Cohort Analysis. American Journal of Cardiology 105(9-Supp-S): 69-70, 2010